Name one drug that vicl has doing over $200 million with sales growing at faster than 5%??
A real reality check is when you look around you and see things are going opposite of what you would have hoped for but have the gumption to say you made a mistake and go with the flow.....drop vicl and tout ISIS. t
The future is bleak for vicl. Never was good, but now it is bleak. Many more biotechs in that field with much better technology and not the bad name that vicl hasn't over the last 18 mos. t
The terrorists copied them. If you are Greek you should change your nationality as ISIS is from Greek mythology and you could get caught up in the turmoil too. t
Prune juice would have performed much better than vicl's last vaccine trial where the placebo treated group did much better than the vicl vicious vaccine did. t
You need to READ a little too. I never said you cut and paste ANYTHING. Your messages, a couple at least all mention AMRN. And did you or did you not accuse me of being in AMRN, losing money, and having some kind of anger because of it?? There is no burden on me good buddy, only relaying information to responsible adults who can make their own decision about whether or not RNN is a high risk investment that they want to participate in. It is the other side from someone like you who doesn't know anything about the science and we get your whole life history in regards to trading......and NOT any information. You don't know what I do or don't know, but you certainly don't know any science at all. Cutting and pasting but backing up what I say, catch your train trader:))
NOT from vicl, they have only had a recent study where the placebo badly outperformed the treatment group. The info was delayed as long as possible by the CEO, but finally he came out kicking and screaming and had to admit that the placebo did in fact do a better job than the treatment group. But that was over six months ago. Since that time the company has had little or no news and the whole world in vaccine medicine has passed them by. t
What is even more scarier is the fact that NVS announced they too are getting into CART technology for vaccines. So you have a big pharma joining these other biotechs that have all ramped up to leave vicl in the dust in regards to technology and thus the competition gets hotter, vicl share gets cooler, the CEO gets dumber, and the shareholder gets closer to being homeless. Reporting from outside the vicl headquarters where there are no lights on at 3:15pm this is t.
He seems dummer than a door nail with an ego to boot. t
Hi KG, and thank you for the kind words. This revere gear phildo wants to put words into a person's mouth and thoughts. Never did I bring up AMRN. A worthless company that was trying to compete with ISIS ApoC III inhibitor and they last the battle with the FDA today. ISIS ApoCIII inhibitor lowers triglycerides by 75%, raises good HDL by 55%(I've checked that out with three different sources), lowers your ApoCIII levels....which in themselves are CV risk increasers, lowers your insulin resistance. Vascepa will never come close. Moreover you have about 2 to 4% amount of myalgias and arthralgias. Just because the drug was approved doesn't mean that will be very good at what it was supposed to do and ISIS ApoCIII inhibitor will eat it up. Also, ISIS has an Lp(a) inhibitor that lowers Lp(a) by over 90%. Vascepa if it is lucky will lower your Lp(a) by about 15%. So this rumdum with two years experience and pseudo macho thing wants to tell us that we love AMRN and that his two years experience is telling him that RNN has no potential. He does read the National Enquirer I guess. Hope to get together with you and G sometime soon. Good luck in your investing, stay in touch. t
This despite near record highs in all of the indexes. t
I can't even make a pancake, but if you want yo play twenty questions this what I do. I have a question for you. What is the only cranial nerve that completely decussates and where? Believe what I post or don't. t
CP, I think the drug to treat Lp(a) has huge potention. People afflicted with that problem genetically have a rough way to go because condition does no respond to the usual lipid lowering risk maneuvers. Watching your diet, exercising, nothing helps but lowering your Lp(a) directly does. PCSK9 inhibitors have found to lower it by about 20-30%. ISIS drug has been found to lower it by about 90%. Moreover, one of the biggest populations with prevalence is people native to India. t
All of the vicl minions are going to be continuously jealous as this plays out. They have programs for HD, ALS, TTR-amyloidosis, etc. Their flag-ship product their ApoCIII inhibitor lowers ApoCIII by 80% which is a CV risk factor in and of itself. It lowers your triglycerides by 75%, raises your HDL by 55%, decreases insulin resistance, and will have maybe two or more orphan indications and then go mainstream. The triglyceride/HDL ratio may be the most important ration in regards to CV risk. A recent published paper on this drug was supported by NovoNordisc. They could be the eventual owners of this drug. An upfront payment of from $500 to $700 million with milestone payments, and double digit royalties for the mainstream use and ISIS might keep the one or two Orphan indications for themselves. t
Akt confers cisplatin chemoresistance in human gynecological carcinoma cells by modulating PPM1D stability
Molecular Carcinogenesis, 09/11/2014 Clinical Article
Ali AY, et al. – Ovarian cancer (OVCA) and cervical cancer (CECA) are lethal gynecological malignancies. Cisplatin (CDDP) and platinum derivatives are first–line chemotherapeutics, and their resistance impedes successful treatment. It has been established that protein phosphatase magnesium–dependent 1 D (PPM1D) confers CDDP resistance in gynecological cancer cells by deactivating p53. This study has established that PPM1D plays an important role in promoting CDDP resistance, and as a novel downstream target of Akt (also known as protein kinase B), PPM1D mediates its action in conferring CDDP resistance in gynecological cancer cells.
CDDP induced PPM1D down–regulation through proteasomal degradation in sensitive CECA cells.
CDDP induced PPM1D nuclear localization in resistant CECA cells, and nuclear exclusion in sensitive CECA cells and OVCA xenografts.
Over–expression of active Akt in sensitive CECA cells stabilized PPM1D content through inhibition of CDDP–induced PPM1D down–regulation.
Inhibition of Akt activity in resistant OVCA cells leads to decreased PPM1D stability and CDDP–induced down–regulation in resistant CECA cells.
PPM1D is highly expressed in human ovarian tumor subtypes and in a tissue microarray panel of human ovarian tumors.
Have to throw in some spamming on ISIS, will be over 100 by second half of next year. t
You are on the wrong board so you should scram....no wait we'll need you for more quotes on the vicl/ISIS ratio. :))) t
Please let me know how vicl and ISIS are doing price-wise. TIA, t
One last thing to chew on. Statins drugs are wonderful, but with their lipid lowering effects, and pleotrophic effects they still only reduce CV risk by about 30%. Using this juxta at subtherapeutic levels, or even those few that will be able to tolerate more than 20mg per day year in and year out may not lower CV risk as much as people think. You throw in the $350K price and this is still a moving experiment. Through in all the negatives like I noted and it might be worse. In patients who don't have CV disease eating fruit lowers your risk by 40% for CV disease in research that just came out. So everything is relative, but the lowering of these patients risk more than the simple LDL reduction you see with juxta may be the secret. Just like statins don't work that well in CKD patients with stage IV, and stage V, this juxta may not do what people think it should even if it makes targets with LDL, and worse it causes negative metabolic problems with its use which hasn't been fully studied. The background population with Mipo is ten fold over that with juxta, this latest study had five times more patients than juxta had in their little 23 patient study, and this last study is REAL WORLD CV RISK REDUCTION over a two year period of time. I know that a lot people won't believe me, and I just say due your own DD......but in the end it isn't ego.....IT'S YOUR MONEY. t
ISIS ApoCIII inhibitor also lowers your HgbA1c in diabetics by over 1.5%. And here we sit talking about a drug from AEGR that is over 25 years old, that has huge baggage, with a company that calls themselves a BIOTECH, that has no new drugs in the platform, that has as their Mission statement that they are in the business of treating orphan DISEASESSSSS with one drug, and no research team, with no earnings, with increased competition, and a CEO that is still looking for tribes all over the world that have HoF so he can use the drug on. This in an age with Google, satellites, and all the internet.....and he's going to ferret out the addtional patients that will make it all worth while to spend money the company doesn't have to dig up those patients. Like that one comedian always says..."What a country" I say "What a COMPANY." t
ISIS will not pursue a new version of Mipomersen because they may have fallen upon the master modulator for lipids, that being their ApoCIII inhibitor. The newly recognized ratio of triglycerides/HDL may be the most important easily figured out risk assessment. This drug will lower your ApoCIII about 80% which in and of itself is a CV risk reducer, the drug will also lower your triglycerides by 75%, and raise your HDL by 55%. Moreover, the HDL raised is naturally produced, and acts like the cardioprotective form of HDL. Juxta lowers your HDL, and with the liver fat increasing, and having the fatty infilatration to the small intestine.....unique to juxta of all the lipid lowering agents this drug is locked in in regards to potential. And for the pediatric population with the potential vitamin deficiencies like Vitamin D.....which is being found out to be super important in lowering your CV risk profile as well as a ton of other things including your risk for bowel CA, and even such things as glaucoma......the secret wish of Mr. Beer to get this approved for children will vanish fast. Can't emphasize it enough, a one drug company with a one drug in reserve in the platform....THAT IS IN EXACTLY THE AREA OF MEDICAL TREATMENT bought by Mr. Beer to eliminate competition makes this company highly susceptible for BK, and with them going against the likes of SNY, and AMGN, and also now PFE that is a scary situation because they will get some of the same that Mr. Beer is counting for this drug. As an aside. the biggest curve ball may come from ALNY's PCSK9 inhibitor that works via RNAi mechanism, as their PCSK9 may outperform the Mab's, and work with statins in a more synergistic way so as to outperform what people expect from PCSK9 inibitors. Outside chance for that one CEPT inhibitor, Mipo's data looking good, PCSK9 inhibitors......ALNY's which could be the real dark horse, ISIS ApoCIII inhibitor that could be the master modulator of lipids, and ISIS new drugs. t